Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-9,619
Closed -$319K 133
2023
Q3
$319K Buy
9,619
+809
+9% +$28.6K 0.21% 84
2023
Q2
$323K Buy
8,810
+600
+7% +$23.4K 0.21% 84
2023
Q1
$335K Buy
8,210
+1,460
+22% +$63.1K 0.21% 81
2022
Q4
$346K Sell
6,750
-1,614
-19% -$77.4K 0.23% 72
2022
Q3
$366K Buy
8,364
+960
+13% +$46.6K 0.26% 61
2022
Q2
$388K Buy
7,404
+259
+4% +$13.2K 0.3% 59
2022
Q1
$370K Sell
7,145
-1,134
-14% -$58.8K 0.26% 65
2021
Q4
$489K Buy
8,279
+1,948
+31% +$96.5K 0.33% 50
2021
Q3
$272K Buy
+6,331
New +$280K 0.24% 79

Other funds holding PFE

Blue Barn Wealth's PFE Position: Q4 2023 in Review

Blue Barn Wealth sold out of Pfizer (PFE) in Q4 2023, closing a stake of 9,619 shares — an estimated $319K sold.

Blue Barn Wealth first reported a position in PFE in Q3 2021 and held it in 9 quarters. The position peaked at $489K in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

  • Blue Barn Wealth reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
  • Blue Barn Wealth sold 9,619 Pfizer shares in Q4 2023, an estimated $319K.
  • Blue Barn Wealth first reported a position in Pfizer in Q3 2021 and held it in 9 quarters.
  • Blue Barn Wealth's Pfizer position peaked at $489K in Q4 2021.
  • 2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Blue Barn Wealth's 13F filing for Q4 2023, filed 6 Feb 2024.